Track topics on Twitter Track topics that are important to you
Second quarter earnings for the big pharma were uneventful, but commentary on business development and the biosimilar market were illuminating.
Original Article: Pfizer still mum on BD, frustrated by biosimilar marketNEXT ARTICLE
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...